EndoTrap® FAQs
- What is EndoTrap®?
- EndoTrap® is an affinity chromatography resin based on a bacteriophage-derived protein that binds endotoxins with high specificity. The ligand targets a conserved region of the lipopolysaccharide (LPS) inner core and binds endotoxins from Gram-negative bacteria. It is not an antibody, a synthetic peptide, or a Polymyxin B-based resin. The same matrix can be used in batch or column (flow-through) mode. For regulatory documentation, toxicological data, a Regulatory Support File, and a leakage ELISA for EndoTrap® HD are available.
- How do batch mode and column mode work?
- In batch mode, settled resin is added directly to the sample. Test contact times of about 3 to 20 minutes to find suitable conditions. In column mode, pack depyrogenated resin as a 50% slurry in sterile buffer, or use ready-to-use columns. Column mode is usually easier and more efficient than batch mode. For any format, optimize pH, ionic strength, temperature, and contact time for your application to maximize endotoxin removal and sample recovery.
- How do ready-to-use flow-through columns work?
- EndoTrap® is a flow-through system. On a 1 ml column you can process up to 50 ml of sample in total, loading up to 3 ml per pass (an optional funnel allows about 20 to 25 ml per load). One cleaning step means your complete working volume has passed through the column once; regenerate the column between steps. Pre-packed columns and bulk resin for self-packing are available from Lionex (see the product catalogue). Fully automated liquid chromatography systems may be used if run times stay within the limits for your product grade.
- What flow rates should I use?
- Gravity flow is typically about 0.5 ml/min. Do not exceed 1 ml/min on EndoTrap® red; higher rates can compress the gel bed. EndoTrap® HD tolerates higher flow rates. A peristaltic pump may be used at or below these limits; slower flow often improves endotoxin removal. Keep all wetted equipment pyrogen-free.
- What is the binding capacity, and how many cleaning steps do I need?
- EndoTrap® red: 2,000,000 EU/ml resin. EndoTrap® HD: > 5,000,000 EU/ml resin (1 EU = 100 pg LPS). For HD, aim not to exceed about 2.5 million EU per ml of resin per run. Repeat cleaning steps to reach lower endotoxin levels (red: at least three cycles; HD: up to ten). Each pass can reduce endotoxin by about two log steps (HD: about three log steps). For reliable planning, keep total LPS applied within about 30 to 50% of the stated capacity. With repeated use, typical targets include about 0.005 EU/ml for buffers, about 0.1 EU/ml for proteins (removal efficiency may fall at very low levels), and about 0.01 EU/ml for DNA. Performance depends on sample properties; if you do not reach your target after three cleaning steps (each followed by regeneration), contact Lionex technical support.
- Can EndoTrap® be regenerated, stored, or sterilized?
- Yes. Use the supplied regeneration buffer. EndoTrap® red can be reused at least three times; EndoTrap® HD more than ten times, without loss of endotoxin removal efficiency under recommended conditions. Store resin in regeneration buffer with 0.02% sodium azide to limit microbial growth. Do not autoclave the material. Washing with 30% ethanol is acceptable; avoid sodium hydroxide, which may denature the ligand.
- When does my sample elute, and what if flow is slow?
- The void volume of a 1 ml column is about 0.3 to 0.5 ml; sample usually elutes immediately afterward. If there is slight retention on the matrix, wash with equilibration buffer, collect fractions, and pool as needed. Gravity flow through a 1 ml column at about 0.5 ml/min takes roughly 20 minutes for 10 ml. If flow is much slower, check for air bubbles (for example after transport): centrifuge the closed column at about 1000 × g for 5 minutes, gently reseat the top frit with a pyrogen-free pipette, or remove bubbles from the bottom using a syringe and endotoxin-free tubing while the column contains buffer.
- Which samples and conditions are compatible?
- Substances that pass through the column can be processed, including proteins, peptides, antibodies, and plasmid DNA. EndoTrap® removes endotoxin from proteins with isoelectric points (pI) from about 5 to 9. EndoTrap® HD is also suitable for plasmid DNA, RNA, and plant extracts. A working concentration of about 1 to 10 mg/ml protein is recommended (higher concentrations have been tested). The resin is active at 4 °C and at room temperature. Up to 2 M urea at pH 7 is generally compatible. EndoTrap® HD can be used with up to 1 M NaCl; EndoTrap® red up to 250 mM NaCl (best below 100 mM).
- What agents inhibit EndoTrap® or damage the ligand?
- EndoTrap® HD is inhibited by EDTA and other calcium chelators (EGTA, HEDTA, NTA, citrate), ammonium sulphate, SDS, and other detergents. EndoTrap® red is inhibited by salt concentrations above 250 mM, GdnHCl, ammonium sulphate, SDS, and other detergents. Dithiothreitol (DTT) interferes with EndoTrap® red; EndoTrap® HD can be used with up to 10 mM DTT or pre-washed with DTT. Proteases may destroy the ligand: use conditions that reduce protease activity (for example 4 °C) or adjust the buffer (pepsin, for example, is inactive above pH 6).
- Does EndoTrap® bind pyrogens and yeast extract?
- Most pyrogenic activity relevant to bioprocessing comes from bacterial endotoxin (LPS). EndoTrap® binds conserved LPS structures from Gram-negative bacteria. Yeast cell walls do not contain endotoxin, but yeast extracts may be contaminated with LPS from bacteria in laboratory water systems; EndoTrap® can remove that endotoxin during downstream processing.
Your question isn't covered here? Please contact us: sales@lionex.de
LIOFeron® TB/LTBI FAQs
- What kind of test is LIOFeron® TB/LTBI?
- LIOFeron® TB/LTBI is an interferon-gamma release assay (IGRA) for professional laboratory use. It detects cellular immune responses to Mycobacterium tuberculosis-specific antigens in whole blood after incubation in stimulation tubes, with interferon-gamma quantified by ELISA. Like other IGRAs, it indicates infection with the TB pathogen; it is not a direct test for culturable bacilli.
- Can LIOFeron® TB/LTBI distinguish active TB from latent TB infection (LTBI)?
- No. As with other IGRAs, LIOFeron® TB/LTBI does not by itself separate active tuberculosis from LTBI. Results must be interpreted together with clinical findings and other diagnostic procedures according to local guidelines.
- Can we use ELISA readers or platforms from different manufacturers?
- Yes. The current LIOFeron® TB/LTBI ELISA is designed for use on open systems. Follow the Instructions for Use for plate layout, incubation, and read parameters on your instrument.
- Is there software to analyse LIOFeron® TB/LTBI ELISA results?
- Yes. Lionex provides standalone LIOFeron® TB/LTBI Analysis Software for automated evaluation of ELISA data, including options to import raw data from supported readers and platforms. See the software page for downloads and documentation.
- Do we need additional reagents beyond the kit?
- No. The kit includes blood stimulation tubes and ELISA reagents required to run the assay as described in the Instructions for Use. Standard laboratory consumables (pipette tips, etc.) are not included.
- How should blood be collected for the assay?
- In typical practice, lithium-heparin whole blood is collected in appropriate primary tubes and aliquoted into the kit stimulation tubes. Alternatively, blood obtained through standard collection devices may be added directly to the kit tubes, which contain lithium heparin. Mix and incubate as specified in the IFU.
- Are the blood stimulation tubes screw-cap tubes?
- No. The tubes use push-pull caps: pull to open and press firmly to close. Close caps in two stages as described in the IFU so tubes seal properly during incubation.
- Is a CO₂ incubator required?
- A CO₂ incubator is not required; incubation is performed as specified in the Instructions for Use at the recommended temperature. A CO₂ incubator may be used if that is your laboratory’s validated workflow and it is compatible with the IFU.
- When are IGRA tests useful in settings with high TB burden?
- IGRAs support detection of M. tuberculosis infection when used in appropriate clinical and public-health contexts, for example, when symptoms or risk factors suggest TB disease and an infection test adds useful information, or when screening for LTBI is indicated before immunosuppressive therapy (such as TNF-alpha antibodies). They are not a stand-alone method to determine the prevalence of active TB disease in a population and do not replace microbiological confirmation where active TB is suspected. In population screening, they are useful when the goal is to determine the prevalence of latent infections with TB pathogen (LTBI).
- What if LIOFeron® TB/LTBI results disagree with another IGRA or test?
- Discordant interferon-gamma release assay results occur in clinical practice for various reasons. Interpret any IGRA in the full clinical context, no single brand or method represents a universal reference standard for latent infection. Use complementary assessment as indicated: clinical evaluation, imaging, microbiology, nucleic acid testing, tuberculin skin testing, and local guidelines. For laboratory implementation, involve your responsible clinician or laboratory director when contacting Lionex to help us evaluate your specific requirements.
Your question isn't covered here? Please contact us: sales@lionex.de
Why partners trust Lionex
Made in Germany
Trusted quality and manufacturing
Extensive Portfolio
Extensive diagnostic and research portfolio
Full Support
Comprehensive technical and regulatory support
Partner Solutions
Solutions for clinical, research and OEM partners
Worldwide
Worldwide distribution